Related Experiment Video
Updated: Jun 13, 2026

13:19
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Improvement of psoriasis during sunitinib therapy for renal cell carcinoma
Sujata Narayanan1, Kristina Callis-Duffin, Julia Batten
1Department of Internal Medicine, University of Utah, Salt Lake City, USA.
The American Journal of the Medical Sciences
|April 28, 2010
Abstract:
Sunitinib is an oral tyrosine kinase inhibitor, which is indicated for the treatment of renal cell carcinoma and gastrointestinal stromal tumors. The authors report the case of a patient who underwent treatment for renal cell carcinoma and noted additional benefit by improvement in his psoriatic skin lesions. This may be attributed to the antiangiogenic activity of sunitinib by inhibition of vascular endothelial growth factor receptors.